Compare Globus Medical Inc. Class A Common Stock (GMED) vs Globalstar (GSAT) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

GSAT trades at $82.68, down 0.43% with a bullish technical outlook. The company shows strong gross margins at 62.25% but faces profitability challenges with negative net income margins. Recent satellite launches and infrastructure expansion in Greece signal growth potential, though earnings have consistently missed expectations.

Investment outlook remains mixed with 40% analyst buy ratings but persistent losses. Key risks include execution challenges and high valuation multiples. Positive cash flow and strategic developments provide upside catalysts, but profitability improvement is critical for sustained shareholder value.